AAO 2020: Phase II Study Identifies Once-Daily Dosing of Omidenepag for Use in Phase III Trials
Twice-daily dosing increased adverse events without improving efficacy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.